文献速递其他结缔组织病

Lenabasum 在成人系统性硬化症中的 II 期随机安慰剂对照试验:安全性与疗效

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2020-07-17

这项在美国 9 个硬皮病中心开展的随机双盲安慰剂对照 II 期研究,纳入病程≤6 年、标准治疗稳定的成人弥漫性皮肤型系统性硬化症(dcSSc)患者,比较 lenabasum(n=27)与安慰剂(n=15)的安全性和疗效。结果显示 lenabasum 组不良事件发生率为 63%、安慰剂组为 60%,无与 lenabasum 相关的严重不良事件;lenabasum 组 CRISS 评分中位数在第 16 周升至 0.33,安慰剂组为 0.00(P=0.07),炎症与纤维化通路基因表达及皮肤活检组织学表现改善(均 P≤0.05)。

要点

  • lenabasum 组与安慰剂组不良事件发生率相近(63% vs 60%),无与 lenabasum 相关的严重不良事件。
  • 第 16 周 CRISS 评分中位数 lenabasum 组为 0.33、安慰剂组为 0.00,组间比较 P=0.07。
  • lenabasum 组炎症与纤维化通路基因表达降低、皮肤活检组织学改善(均 P≤0.05)。

核心结论

  • 尽管该 II 期研究疗程短、样本量小,结果提示 lenabasum 可改善 dcSSc 的疗效结局及 underlying 疾病病理,且安全性良好。

研究设计与样本

  • 随机、双盲、安慰剂对照 II 期研究,在美国 9 个系统性硬化症诊所开展。
  • 纳入病程≤6 年、标准治疗稳定的成人 dcSSc 患者,随机接受 lenabasum(n=27)或安慰剂(n=15)。
  • lenabasum 剂量为 5 mg 每日一次、20 mg 每日一次或 20 mg 每日两次共 4 周,随后 20 mg 每日两次共 8 周。
  • 在第 4、8、12、16 周评估安全性和疗效。

主要发现

  • 不良事件发生率 lenabasum 组为 63%、安慰剂组为 60%,无与 lenabasum 相关的严重不良事件。
  • 与安慰剂相比,lenabasum 治疗与 CRISS 评分及评估整体疾病、皮肤受累和患者报告功能的其他疗效指标更大幅度改善相关。
  • lenabasum 组 CRISS 评分中位数在研究期间升高,第 16 周达 0.33,安慰剂组为 0.00(双侧混合效应模型重复测量分析 P=0.07)。
  • 与安慰剂组相比,lenabasum 组炎症和纤维化通路基因表达降低,皮肤活检组织学显示炎症和纤维化改善(均 P≤0.05)。

关键数值与推荐

  • CRISS 评分中位数第 16 周 lenabasum 组 0.33、安慰剂组 0.00,P=0.07(双侧混合效应模型重复测量分析)。
  • 炎症与纤维化通路基因表达及皮肤活检组织学改善的组间比较均 P≤0.05。

临床怎么用

  • 该 II 期研究提示 lenabasum 在 dcSSc 中安全性良好并可能改善疗效结局与疾病病理,但 CRISS 组间差异未达统计学显著性,需更大规模试验验证。

局限性

  • 研究疗程短,且样本量小(lenabasum 组 n=27、安慰剂组 n=15)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the safety and efficacy of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc). METHODS: A randomized, double-blind, placebo-controlled, phase II study was conducted at 9 SSc clinics in the US. Adults with dcSSc of ≤6 years' duration who were receiving stable standard-of-care treatment were randomized to receive lenabasum (n = 27) or placebo (n = 15). Lenabasum doses were 5 mg once daily, 20 mg once daily, or 20 mg twice daily for 4 weeks, followed by 20 mg twice daily for 8 weeks. Safety and efficacy were assessed at weeks 4, 8, 12, and 16. RESULTS: Adverse events (AEs) occurred in 63% of the lenabasum group and 60% of the placebo group, with no serious AEs related to lenabasum. Compared to placebo, lenabasum treatment was associated with greater improvement in the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score and other efficacy outcome measures that assessed overall disease, skin involvement, and patient-reported function. The median CRISS score increased in the lenabasum group during the study, reaching 0.33, versus 0.00 in the placebo group, at week 16 (P = 0.07 by 2-sided mixed-effects model repeated-measures analysis). Gene expression in inflammation and fibrosis pathways was reduced, and inflammation and fibrosis were improved on histologic evaluation of skin biopsy specimens, in the lenabasum group compared to the placebo group (all P ≤ 0.05). CONCLUSION: Despite a short trial duration in a small number of patients in this phase II study in dcSSc, our findings indicate that lenabasum improves efficacy outcomes and underlying disease pathology with a favorable safety profile.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Spiera R, Hummers L, Chung L, et al. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol. 2020. PMID: 32336038. doi:10.1002/art.41294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。